Background: Generic, low-cost, nevirapine (NVP)-based antiretroviral therapy (ART) has improved survival in HIV-infected individuals living in resource-limited settings. However, there is concern about the potential hepatotoxicity of these regimens. Methods: The authors conducted a prospective study of persons initiating self-pay Triomune or Maxivir therapy in Kampala, Uganda. Results: The 97 study participants were predominantly women (64%), median age was 35 (interquartile range [IQR] 30-40), median CD4 at baseline was 56 cells/mm3 (IQR 8-138), and 19% had lifetime alcohol problems (CAGE ≥ 2). Severe liver enzyme elevations (LEEs) of grade 3-4 were rare (2.2%); however, 1 patient died in the setting of grade 4 LEEs. Grade 1-4 LEEs occurred among 22.2% of participants, and 9.8% had new grade 1-4 LEEs after the initiation of treatment. Discussion: The authors found that LEEs were common but that severe hepatotoxicity in persons initiating NVP-based ART was infrequent yet potentially life-threatening. Monitoring for NVP-related severe hepatic toxicity should be part of expanding antiretroviral treatment programs in resource-limited settings.
Laurent C., Kouanfack C., Koulla-Shiro S., et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicenter trial. Lancet. 2004 ;364(9428): 29-34.
2.
FDA Public Health Advisory for Nevirapine (Viramune). US Food and Drug Administration. Available at: http://www.fda.gov/cder/drug/advisory/Nevirapine.htm. Accessed October 21, 2005.
3.
Sulkowski MS , Thomas DL, Mehta SH, Chaisson RE, Moore RDHepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182-189.
4.
O'Brien ME, Clark RA, Besch CL, Myers L., Kissinger P.Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr.2003;34(4):407-414.
5.
van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts ACIncidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol.1999;20(3):290-294.
6.
Mocroft A., Youle M., Moore A., et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS.2001;15(2):185-194.
7.
d'Arminio Monforte A., Lepri AC, Rezza G., et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14(5):499-507.
8.
Sulkowski MS , Thomas DL, Chaisson RE, Moore RDHepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA.2000;283(1):74-80.
9.
Ena J., Amador C., Benito C., Fenoll V., Pasquau F.Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS.2003;14(11):776-781.
10.
Martin-Carbonero L., Nunez M., Gonzalez-Lahoz J., Soriano V.Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIVClin Trials. 2003;4(2): 115-120.
11.
Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GKPredictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr.2006;43 (3):320-323.
12.
Oyugi JH, Byakika J., Ragland K., et al. Adherence predicts viral suppression while treatment interruptions predict drug resistance in HIV+ individuals purchasing fixed-dose combination generic antiretroviral therapy in Kampala, Uganda. 2006; Under review.
13.
Babor T., Higgins-Biddle J., Saunders J., Monteiro MGThe Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. Geneva, Switzerland: World Health Organization, Department of Mental Health and Substance Dependence; 2001 .
14.
Mayfield D., Mcleod G., Hall P.The CAGE Questionnaire: validation of a new alcoholism screening instrument . Am J Psychiatry.1974;131:1121-1123.
15.
Justice AC, Holmes W., Gifford AL, et al. Development and validation of a self-completed HIV symptom index . J Clin Epidemiol.2001;54(Suppl 1): S77-S90.
16.
van Leth F. , Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253-1263.
17.
Sanne I., Mommeja-Marin H., Hinkle J., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis.2005;191 (6):825-829.
